New injection could help nasal polyp sufferers avoid surgery
NCT ID NCT06516302
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests an experimental drug called GR1802 for adults with severe chronic rhinosinusitis with nasal polyps. The goal is to see if the drug can shrink polyps, ease congestion, and reduce the need for surgery or steroids. 228 participants will receive either GR1802 or a placebo every two weeks for 13 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GR1802 (an experimental drug given as an injection)
- What this could lead to
- If it works, this could provide a new treatment option for people with severe nasal polyps, potentially reducing the need for surgery and steroid use.
- What could go wrong
- This is still an experimental drug in a Phase 3 trial. It may not work better than placebo, and side effects are possible. Results are not yet available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Tongren Hospital, Capital Medical University
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shrink nasal polyps and restore smell?
- Triple-Action nasal spray could ease chronic sinusitis
- 3D-Printed nose models could boost sinus rinse results
- Sinus surgery may ease sleep problems in nasal polyp patients
- Real-World check: do new biologics really help severe nasal polyps?
- New study digs into how mepolizumab changes nose bacteria and genes in asthma patients